BR0209034A - Proteìnas de envoltório de hcv glicosiladas no núcleo - Google Patents

Proteìnas de envoltório de hcv glicosiladas no núcleo

Info

Publication number
BR0209034A
BR0209034A BR0209034-1A BR0209034A BR0209034A BR 0209034 A BR0209034 A BR 0209034A BR 0209034 A BR0209034 A BR 0209034A BR 0209034 A BR0209034 A BR 0209034A
Authority
BR
Brazil
Prior art keywords
proteins
hcv
wrap
glycosylated
nucleus
Prior art date
Application number
BR0209034-1A
Other languages
English (en)
Inventor
Erik Depla
Alfons Bosman
Geert Deschamps
Erwin Sablon
Manfred Suckow
Isabelle Samson
Gert Verheyden
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR0209034A publication Critical patent/BR0209034A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PROTEìNAS DE ENVOLTóRIO DE HCV GLICOSILADAS NO NúCLEO". A presente invenção relaciona-se às proteínas de envoltório de HCV, ou às suas partes, as quais são o produto da expressão em células eucarióticas. Mais particularmente, as ditas proteínas de envoltório de HCV são caracterizadas pelo fato de que, em média, até 80 % de seus sítios de N-glicosilação são glicosilados no núcleo. Destes sítios N-glícosilados, mais do que 70 % são glicosilados com uma oligomanose tendo uma estrutura definida por Man(8 a 10)G1cNAc(2) . Além disso, a razão da oligomanose com estrutura Man (7)-G1cNAc (2) sobre a oligomanose com estrutura Man (8)G1cNAc (2) é menor do que, ou igual a, 0,45. Menos do que 10 das oligomanoses são terminadas com uma <244>1,3 manose ligada. As proteínas de envoltório de HCV da invenção são particularmente adequadas para propósitos diagnósticos, profiláticos e terapêuticos. Uma célula eucariótica adequada para a produção das proteínas de envoltório de HCV da invenção e uma célula de Hansenula.
BR0209034-1A 2001-04-24 2002-04-24 Proteìnas de envoltório de hcv glicosiladas no núcleo BR0209034A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01870088 2001-04-24
US30560401P 2001-07-17 2001-07-17
PCT/BE2002/000064 WO2002086101A2 (en) 2001-04-24 2002-04-24 Core-glycosylated hcv envelope proteins

Publications (1)

Publication Number Publication Date
BR0209034A true BR0209034A (pt) 2005-02-01

Family

ID=34072546

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209034-1A BR0209034A (pt) 2001-04-24 2002-04-24 Proteìnas de envoltório de hcv glicosiladas no núcleo
BR0209033-3A BR0209033A (pt) 2001-04-24 2002-04-24 Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0209033-3A BR0209033A (pt) 2001-04-24 2002-04-24 Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes

Country Status (20)

Country Link
US (3) US7314925B2 (pt)
EP (3) EP1381671A2 (pt)
JP (2) JP4261195B2 (pt)
KR (1) KR100950104B1 (pt)
CN (1) CN1636050A (pt)
AR (3) AR035867A1 (pt)
AU (3) AU2002257392B2 (pt)
BR (2) BR0209034A (pt)
CA (3) CA2443781A1 (pt)
CZ (1) CZ20032853A3 (pt)
HU (1) HUP0303924A2 (pt)
MX (2) MXPA03009632A (pt)
NZ (2) NZ529019A (pt)
OA (1) OA13092A (pt)
PL (1) PL366621A1 (pt)
RU (1) RU2274643C2 (pt)
SK (1) SK13142003A3 (pt)
WO (3) WO2002085932A2 (pt)
YU (1) YU84103A (pt)
ZA (3) ZA200308274B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
WO2002085932A2 (en) * 2001-04-24 2002-10-31 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
AU2003283365A1 (en) * 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4371739B2 (ja) * 2003-09-02 2009-11-25 株式会社東芝 シリアルａｔａインタフェースを持つ電子機器及びシリアルａｔａバスのパワーセーブ方法
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
JP4885476B2 (ja) * 2004-05-21 2012-02-29 株式会社日本触媒 タンパク質及び／又はペプチドの細胞内導入方法
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1809773B1 (en) * 2004-10-18 2014-07-16 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
CA2651456A1 (en) 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
DE102009044224A1 (de) * 2009-10-09 2011-04-28 PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 Methode zur Produktion von HCV Virus-ähnlichen Partikeln
DK2654785T3 (da) 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
JP2019504638A (ja) * 2015-11-13 2019-02-21 マメドフ、タルラン Ｅｎｄｏ ｈとの同時発現によってインビボｎ−脱グルコシル化組換えタンパク質の産生
EP3184642B1 (de) * 2015-12-22 2019-05-08 bisy e.U. Hefezelle
AU2017332854A1 (en) 2016-09-21 2019-04-11 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
NO177065C (no) * 1988-09-26 1995-07-12 Labofina Sa Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5712087A (en) 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
WO1992001800A1 (en) * 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
ES2188583T3 (es) 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
AU4659993A (en) 1992-07-07 1994-01-31 Merck & Co., Inc. Vaccine comprising mixed pres1+pres2+s and core particle
DK0992580T3 (da) 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
ES2174957T5 (es) * 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
DE69735242T2 (de) * 1996-12-20 2006-09-21 Novo Nordisk A/S N-terminal verlängerte proteine exprimiert in hefe
AU752131C (en) 1997-11-06 2003-12-04 Innogenetics N.V. Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
AU2149899A (en) * 1998-01-23 1999-08-09 Novo Nordisk A/S Process for making desired polypeptides in yeast
TR200003024T2 (tr) 1998-04-17 2000-12-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller.
NZ508797A (en) * 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination
CA2387666A1 (en) 1999-10-27 2001-05-03 Innogenetics N.V. Redox reversible hcv proteins with native-like conformation
WO2002055548A2 (en) 2001-01-11 2002-07-18 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2002085932A2 (en) * 2001-04-24 2002-10-31 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
RU2319505C2 (ru) 2001-12-18 2008-03-20 Иннодженетикс Н.В. Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения
AU2003283365A1 (en) 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides

Also Published As

Publication number Publication date
MXPA03009632A (es) 2004-06-30
CA2443781A1 (en) 2002-10-31
US20030108561A1 (en) 2003-06-12
EP1414942A2 (en) 2004-05-06
SK13142003A3 (en) 2004-11-03
KR100950104B1 (ko) 2010-03-30
JP2004532029A (ja) 2004-10-21
AR035868A1 (es) 2004-07-21
JP4261195B2 (ja) 2009-04-30
MXPA03009626A (es) 2004-06-30
NZ529019A (en) 2004-05-28
JP2004536052A (ja) 2004-12-02
NZ529324A (en) 2005-08-26
KR20030094359A (ko) 2003-12-11
US20030211597A1 (en) 2003-11-13
WO2002085932A3 (en) 2003-03-13
ZA200308274B (en) 2005-01-24
AR035869A1 (es) 2004-07-21
HUP0303924A2 (hu) 2004-03-01
AU2002252856A1 (en) 2002-11-05
WO2002086100A3 (en) 2004-02-19
CN1636050A (zh) 2005-07-06
JP4173741B2 (ja) 2008-10-29
RU2003130955A (ru) 2005-04-20
AR035867A1 (es) 2004-07-21
WO2002086101A3 (en) 2004-02-19
PL366621A1 (en) 2005-02-07
US7238356B2 (en) 2007-07-03
WO2002086100A2 (en) 2002-10-31
RU2274643C2 (ru) 2006-04-20
CZ20032853A3 (cs) 2004-08-18
ZA200308272B (en) 2005-01-24
EP1417298A2 (en) 2004-05-12
AU2002308449B2 (en) 2008-05-29
WO2002085932A2 (en) 2002-10-31
YU84103A (sh) 2006-05-25
US7048930B2 (en) 2006-05-23
OA13092A (en) 2006-11-10
US7314925B2 (en) 2008-01-01
WO2002086101A2 (en) 2002-10-31
US20030152940A1 (en) 2003-08-14
ZA200308277B (en) 2004-07-08
AU2002257392B2 (en) 2007-05-10
BR0209033A (pt) 2005-01-11
CA2443740A1 (en) 2002-10-31
EP1381671A2 (en) 2004-01-21
CA2444006A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
BR0209034A (pt) Proteìnas de envoltório de hcv glicosiladas no núcleo
BR0108354A (pt) Carboidratos antiadesivos
BR0213761A (pt) Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
BR9914932A (pt) Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária
NO20012718L (no) Ekspresjonssystem for faktor VIII
BR0016341A (pt) Fórmula para bebês, processo para preparar um hidrolisado protéico, hidrolisado protéico, e, uso de um hidrolisado protéico
BR9916691A (pt) Processo para preparação de partìculas de amido em um sistema de duas fases
BR9813391A (pt) Composição de epo, preparado farmacêutico e processos para produzir uma composição de epo e para aumentar a atividade especìfica de uma composição de epo
BR0114512A (pt) Suspensão coloidal, sólido pulverulento, processos de preparação, produtos intermediários de processo, especialidade farmacêutica, nutricional, fitossanitária ou cosmética e uso de uma suspensão coloidal estável
BR9608810A (pt) Composição de vacina compreendendo fosfato de polirribosilribitol e processo para a sua fabricação.
BR0015061A (pt) Núcleo de comprimido de polìmero por compressão direta
BR0109405A (pt) Processo para a produção de carrageninas, carrageninas, e, uso destas
AU5297999A (en) Use of a composition
BR9611871A (pt) Diaminopirimidinas composições farmacêuticas contendo as mesmas e seu uso como antibactericidas
BR9815184A (pt) Módulos de mola de material composto com encaixes de fixação formados integralmente
PL367812A1 (en) Alpha-ketoglutarates of active ingredients and compositions containing same
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid&#39;den oluşan antioksidan bileşim
BR9913107A (pt) Derivados de benzoilguanidina, com propriedades vantajosas, processos para sua preparação e seu uso na produção de medicamentos
BR0209820A (pt) Processo para a preparação de formulações sólidas de 3-hidróxi-3-metilbutirato de sódio
BR0315414A (pt) Composições farmacêuticas de lisado de células e processos para a produção e uso destas
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
BR9714525A (pt) Agente de texturização
BR0114060A (pt) Processo para a preparação de delta1-pirrolinas
BR0215296A (pt) Formulações sólidas para proteção de plantas
BR0013421A (pt) Composição para administração tópica,compreendendo 5-metoxipsoraleno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.